Innovent Biologics Doses First Patient in Phase 3 Tigulixostat Study – Next‑Gen Xanthine Oxidase Inhibitor Targets Gout Market
Innovent Biologics, Inc. (HKG: 1801) announced that the first subject has been dosed in the...
Dizal Reports Positive WU‑KONG28 Results – ZEGFROVY First‑Line Win Positions as First Chemo‑Free EGFR exon20ins NSCLC Therapy
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that its multinational Phase 3 WU‑KONG28 study evaluating...
CSPC Pharma’s SYH2082 Wins NMPA Approval – Long‑Acting GLP‑1/GIP Dual‑Biased Agonist Enters Obesity Clinical Trials
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its self‑developed SYH2082, a long‑acting injectable GLP‑1/GIP...
Haihe Biopharma Wins Japan Approval for Risovalisib – First PI3Kα Inhibitor for Ovarian Clear Cell Carcinoma
Haihe Biopharma Co., Ltd. announced that its independently developed selective PI3Kα inhibitor, Risovalisib Mesylate Tablets,...
China NHC Issues Medical Technology Evaluation Procedures – New Framework Triggers Restrictions or Bans on Controversial Clinical Practices
China’s National Health Commission (NHC) issued the “Work Procedures for Evaluating the Clinical Application of...
Medtronic Completes First Penditure Implant in Greater Bay Area – Recapturable LAA Closure System Leverages HK‑Macao Access Policy
Medtronic plc (NYSE: MDT) announced the first clinical implantation of its Penditure left atrial appendage...
3SBio Wins NMPA Approval for SSS06 – Extended‑Half‑Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia
3SBio Inc. (HKG: 1530) announced that China’s National Medical Products Administration (NMPA) has approved SSS06,...
Alphamab Oncology Doses First Patient in JSKN016 Phase III – HER3/TROP2 ADC Targets Heavily Pretreated Triple Negative Breast Cancer
Alphamab Oncology (HKG: 9966) announced first patient dosing in a Phase III clinical study for...
Belief BioMed Secures Macao Approval for BBM‑H901 – China’s First Hemophilia B Gene Therapy Expands to Greater China with Takeda
Belief BioMed announced marketing approval from the Pharmaceutical Administration Bureau of Macao Special Administrative Region...
Sanofi Opens Chengdu Innovation Hub – 600‑Headcount China Operations Center to Drive R&D and Commercial Excellence
Sanofi S.A. (NASDAQ: SNY) has officially opened its China Innovation and Operations Hub in Chengdu,...
AstraZeneca to Build Radioligand Therapy Manufacturing Hub in Guangzhou – Actinium‑225 Facility Targets Asia‑Pacific Cancer Market
AstraZeneca PLC (NASDAQ: AZN) has signed a Memorandum of Understanding with the Guangzhou Economic and...
Novo Nordisk Wins FDA Approval for Wegovy HD 7.2 mg – Higher‑Dose Semaglutide Delivers 21% Weight Loss in STEP UP Trial
Novo Nordisk A/S (NYSE: NVO) announced FDA approval of Wegovy HD (semaglutide) 7.2 mg injection,...
Eli Lilly’s Retatrutide Delivers 2.0% A1C Reduction and 36.6 Lbs Weight Loss in Phase 3 Diabetes Trial – Triple‑Agonist Shows Best‑in‑Class Efficacy
Eli Lilly and Company (NYSE: LLY) announced positive topline results from the Phase 3 TRANSCEND‑T2D‑1...
Pfizer Reports Positive TALAPRO-3 Results – TALZENNA/XTANDI Combo Hits Primary Endpoint in HRR-Mutated Prostate Cancer
Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 TALAPRO-3 study, demonstrating...
Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data
Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901...
Samsung Bioepis Expands Sandoz Partnership – Global Deal for Five Biosimilars Including Entyvio Copycat SB36
Samsung Bioepis Co., Ltd. has expanded its strategic partnership with Sandoz AG (SWX: SDZ), entering...
Abbisko Therapeutics Wins FDA Orphan Drug Designation for ABSK061 – Oral FGFR2/3 Inhibitor Targets Achondroplasia in Pediatric Patients
Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that ABSK061 received Orphan Drug Designation (ODD) from...
Huahai Pharmaceutical Initiates Phase III Trial for HB0025 – PD-L1/VEGF Bispecific Targets First-Line Endometrial Cancer
Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA: 600521) announced the initiation of a Phase III clinical...
Konruns Pharma Wins NMPA Phase III Approval for KC1036 – Multi-Target VEGFR2/AXL Inhibitor Targets Thymic Carcinoma
Konruns Pharmaceutical Co., Ltd. (SHA: 603590) received National Medical Products Administration (NMPA) approval to initiate...
InventisBio’s D-2570 Wins FDA Phase II Clearance – Oral TYK2 Inhibitor Targets Moderate-to-Severe Plaque Psoriasis
InventisBio (Shanghai) Co., Ltd. (SHA: 688382) announced FDA clearance to initiate a Phase II clinical...